Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Lung Cancer

  Free Subscription


Articles published in Br J Cancer

Retrieve available abstracts of 79 articles:
HTML format
Text format



Single Articles


    May 2018
  1. ABOU FAYCAL C, Brambilla E, Agorreta J, Lepeltier N, et al
    The sVEGFR1-i13 splice variant regulates a beta1 integrin/VEGFR autocrine loop involved in the progression and the response to anti-angiogenic therapies of squamous cell lung carcinoma.
    Br J Cancer. 2018 May 24. pii: 10.1038/s41416-018-0128.
    PubMed     Text format     Abstract available


    April 2018
  2. BINS S, Basak EA, El Bouazzaoui S, Koolen SLW, et al
    Association between single-nucleotide polymorphisms and adverse events in nivolumab-treated non-small cell lung cancer patients.
    Br J Cancer. 2018 Apr 26. pii: 10.1038/s41416-018-0074.
    PubMed     Text format     Abstract available


  3. DOHERTY JA, Grieshober L, Houck JR, Barnett MJ, et al
    Nested case-control study of telomere length and lung cancer risk among heavy smokers in the beta-Carotene and Retinol Efficacy Trial.
    Br J Cancer. 2018 Apr 19. pii: 10.1038/s41416-018-0075.
    PubMed     Text format     Abstract available


    February 2018
  4. HAN B, Li K, Zhao Y, Li B, et al
    Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302).
    Br J Cancer. 2018 Feb 13. pii: bjc2017478. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    January 2018
  5. SUN JM, Lee KH, Kim BS, Kim HG, et al
    Pazopanib maintenance after first-line etoposide and platinum chemotherapy in patients with extensive disease small-cell lung cancer: a multicentre, randomised, placebo-controlled Phase II study (KCSG-LU12-07).
    Br J Cancer. 2018 Jan 30. pii: bjc2017465. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  6. ANTONIO M, Saldana J, Linares J, Ruffinelli JC, et al
    Geriatric assessment may help decision-making in elderly patients with inoperable, locally advanced non-small-cell lung cancer.
    Br J Cancer. 2018 Jan 30. pii: bjc2017455. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    November 2017
  7. NANJO S, Hata A, Okuda C, Kaji R, et al
    Standard-dose osimertinib for refractory leptomeningeal metastases in T790M-positive EGFR-mutant non-small cell lung cancer.
    Br J Cancer. 2017 Nov 30. pii: bjc2017394. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    October 2017
  8. THALER J, Sigel C, Beasley MB, Wisnivesky J, et al
    Clinically significant mutations in HIV-infected patients with lung adenocarcinoma.
    Br J Cancer. 2017;117:1392-1395.
    PubMed     Text format     Abstract available


  9. O'SULLIVAN D, Dowling P, Joyce H, McAuley E, et al
    A novel inhibitory anti-invasive MAb isolated using phenotypic screening highlights AnxA6 as a functionally relevant target protein in pancreatic cancer.
    Br J Cancer. 2017;117:1326-1335.
    PubMed     Text format     Abstract available


  10. NI Z, Yao C, Zhu X, Gong C, et al
    Ailanthone inhibits non-small cell lung cancer cell growth through repressing DNA replication via downregulating RPA1.
    Br J Cancer. 2017 Oct 12. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  11. VAHL JM, Friedrich J, Mittler S, Trump S, et al
    Interleukin-10-regulated tumour tolerance in non-small cell lung cancer.
    Br J Cancer. 2017 Oct 10. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  12. GABASA M, Ikemori R, Hilberg F, Reguart N, et al
    Nintedanib selectively inhibits the activation and tumour-promoting effects of fibroblasts from lung adenocarcinoma patients.
    Br J Cancer. 2017;117:1128-1138.
    PubMed     Text format     Abstract available


    September 2017
  13. GREYSTOKE A, Steele N, Arkenau HT, Blackhall F, et al
    SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting.
    Br J Cancer. 2017;117:938-946.
    PubMed     Text format     Abstract available


  14. KOSHIARIS C, Aveyard P, Oke J, Ryan R, et al
    Smoking cessation and survival in lung, upper aero-digestive tract and bladder cancer: cohort study.
    Br J Cancer. 2017 Sep 12. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  15. KLIMOV S, Rida PC, Aleskandarany MA, Green AR, et al
    Novel immunohistochemistry-based signatures to predict metastatic site of triple-negative breast cancers.
    Br J Cancer. 2017;117:826-834.
    PubMed     Text format     Abstract available


    August 2017
  16. LI M, Yang J, Zhou W, Ren Y, et al
    Activation of an AKT/FOXM1/STMN1 pathway drives resistance to tyrosine kinase inhibitors in lung cancer.
    Br J Cancer. 2017 Aug 29. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  17. CALLAHAN CL, Schwartz K, Ruterbusch JJ, Shuch B, et al
    Leukocyte telomere length and renal cell carcinoma survival in two studies.
    Br J Cancer. 2017;117:752-755.
    PubMed     Text format     Abstract available


  18. ADLER NR, Wolfe R, Kelly JW, Haydon A, et al
    Tumour mutation status and sites of metastasis in patients with cutaneous melanoma.
    Br J Cancer. 2017 Aug 8. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  19. CIULEANU TE, Ahmed S, Kim JH, Mezger J, et al
    Randomised Phase 2 study of maintenance linsitinib (OSI-906) in combination with erlotinib compared with placebo plus erlotinib after platinum-based chemotherapy in patients with advanced non-small cell lung cancer.
    Br J Cancer. 2017 Aug 3. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    July 2017
  20. ALEXANDER M, Wolfe R, Ball D, Conron M, et al
    Lung cancer prognostic index: a risk score to predict overall survival after the diagnosis of non-small-cell lung cancer.
    Br J Cancer. 2017 Jul 20. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  21. WINTHER-LARSEN A, Demuth C, Fledelius J, Madsen AT, et al
    Correlation between circulating mutant DNA and metabolic tumour burden in advanced non-small cell lung cancer patients.
    Br J Cancer. 2017 Jul 6. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    June 2017
  22. WEISS GJ, Waypa J, Blaydorn L, Coats J, et al
    A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus).
    Br J Cancer. 2017;117:33-40.
    PubMed     Text format     Abstract available


  23. SAMARENDRA H, Jones K, Petrinic T, Silva MA, et al
    A meta-analysis of CXCL12 expression for cancer prognosis.
    Br J Cancer. 2017;117:124-135.
    PubMed     Text format     Abstract available


  24. CHERNYAVSKIY P, Edmondson EF, Weil MM, Little MP, et al
    High-energy particle beam and gamma radiation exposure, familial relatedness and cancer in mice.
    Br J Cancer. 2017;117:41-50.
    PubMed     Text format     Abstract available


  25. PEDERSEN AB, Horvath-Puho E, Ehrenstein V, Rorth M, et al
    Frozen shoulder and risk of cancer: a population-based cohort study.
    Br J Cancer. 2017;117:144-147.
    PubMed     Text format     Abstract available


  26. BARRERA L, Montes-Servin E, Hernandez-Martinez JM, Garcia-Vicente MLA, et al
    CD47 overexpression is associated with decreased neutrophil apoptosis/phagocytosis and poor prognosis in non-small-cell lung cancer patients.
    Br J Cancer. 2017 Jun 20. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  27. BAHLEDA R, Grilley-Olson JE, Govindan R, Barlesi F, et al
    Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies.
    Br J Cancer. 2017;116:1505-1512.
    PubMed     Text format     Abstract available


    May 2017
  28. KAZDAL D, Harms A, Endris V, Penzel R, et al
    Prevalence of somatic mitochondrial mutations and spatial distribution of mitochondria in non-small cell lung cancer.
    Br J Cancer. 2017 May 30. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  29. KOINIS F, Agelaki S, Karavassilis V, Kentepozidis N, et al
    Second-line pazopanib in patients with relapsed and refractory small-cell lung cancer: a multicentre phase II study of the Hellenic Oncology Research Group.
    Br J Cancer. 2017 May 16. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    March 2017
  30. MACLEOD AK, Acosta-Jimenez L, Coates PJ, McMahon M, et al
    Aldo-keto reductases are biomarkers of NRF2 activity and are co-ordinately overexpressed in non-small cell lung cancer.
    Br J Cancer. 2017 Mar 21. doi: 10.1038/bjc.2017.
    PubMed     Text format    


  31. MURUGANANDAN S, Alfonso H, Franklin P, Shilkin K, et al
    Comparison of outcomes following a cytological or histological diagnosis of malignant mesothelioma.
    Br J Cancer. 2017;116:703-708.
    PubMed     Text format     Abstract available


  32. MALAPELLE U, Mayo de-Las-Casas C, Rocco D, Garzon M, et al
    Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients.
    Br J Cancer. 2017;116:802-810.
    PubMed     Text format     Abstract available


  33. HOLDENRIEDER S, Wehnl B, Hettwer K, Simon K, et al
    Carcinoembryonic antigen and cytokeratin-19 fragments for assessment of therapy response in non-small cell lung cancer: a systematic review and meta-analysis.
    Br J Cancer. 2017 Mar 9. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    February 2017
  34. PRUITT SL, Laccetti AL, Xuan L, Halm EA, et al
    Revisiting a longstanding clinical trial exclusion criterion: impact of prior cancer in early-stage lung cancer.
    Br J Cancer. 2017 Feb 14. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    January 2017
  35. YANG JJ, Zhou Q, Yan HH, Zhang XC, et al
    A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations.
    Br J Cancer. 2017 Jan 19. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  36. BOUCHARD G, Therriault H, Geha S, Bujold R, et al
    Radiation-induced lung metastasis development is MT1-MMP-dependent in a triple-negative breast cancer mouse model.
    Br J Cancer. 2017 Jan 19. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  37. AL-KHAFAJI AS, Davies MP, Risk JM, Marcus MW, et al
    Aurora B expression modulates paclitaxel response in non-small cell lung cancer.
    Br J Cancer. 2017 Jan 17. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  38. WU YL, Sequist LV, Hu CP, Feng J, et al
    EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6.
    Br J Cancer. 2017;116:175-185.
    PubMed     Text format     Abstract available


  39. FAIVRE C, El Cheikh R, Barbolosi D, Barlesi F, et al
    Mathematical optimisation of the cisplatin plus etoposide combination for managing extensive-stage small-cell lung cancer patients.
    Br J Cancer. 2017;116:344-348.
    PubMed     Text format     Abstract available


  40. NEAL RD, Barham A, Bongard E, Edwards RT, et al
    Immediate chest X-ray for patients at risk of lung cancer presenting in primary care: randomised controlled feasibility trial.
    Br J Cancer. 2017 Jan 10. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  41. KIM H, Sung JY, Park EK, Kho S, et al
    Regulation of anoikis resistance by NADPH oxidase 4 and epidermal growth factor receptor.
    Br J Cancer. 2017;116:370-381.
    PubMed     Text format     Abstract available


    November 2016
  42. GROSSI F, Rijavec E, Genova C, Barletta G, et al
    Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy.
    Br J Cancer. 2016 Nov 29. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  43. MACLEOD AK, Acosta-Jimenez L, Coates PJ, McMahon M, et al
    Aldo-keto reductases are biomarkers of NRF2 activity and are co-ordinately overexpressed in non-small cell lung cancer.
    Br J Cancer. 2016 Nov 8. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  44. CHEN HM, Tsai CM, Wu YC, Lin KC, et al
    Effect of walking on circadian rhythms and sleep quality of patients with lung cancer: a randomised controlled trial.
    Br J Cancer. 2016 Nov 3. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  45. WALKER AJ, Baldwin DR, Card TR, Powell HA, et al
    Risk of venous thromboembolism in people with lung cancer: a cohort study using linked UK healthcare data.
    Br J Cancer. 2016 Nov 1. doi: 10.1038/bjc.2016.
    PubMed     Text format    


    October 2016
  46. COURTIN A, Smyth T, Hearn K, Saini HK, et al
    Emergence of resistance to tyrosine kinase inhibitors in non-small-cell lung cancer can be delayed by an upfront combination with the HSP90 inhibitor onalespib.
    Br J Cancer. 2016;115:1069-1077.
    PubMed     Text format     Abstract available


  47. ROBINSON LA, Jaing CJ, Campbell CP, Magliocco A, et al
    Reply to: Comment on 'Molecular evidence of viral DNA in non-small cell lung cancer and non-neoplastic lung'.
    Br J Cancer. 2016 Oct 20. doi: 10.1038/bjc.2016.
    PubMed     Text format    


  48. PONZETTO A, Figura N, Holton J
    Comment on 'Molecular evidence of viral DNA in non-small cell lung cancer and non-neoplastic lung'.
    Br J Cancer. 2016 Oct 20. doi: 10.1038/bjc.2016.
    PubMed     Text format    


    September 2016
  49. HUANG J, Mondul AM, Weinstein SJ, Koutros S, et al
    Serum metabolomic profiling of prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial.
    Br J Cancer. 2016 Sep 27. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  50. MALHOTRA J, Waterboer T, Pawlita M, Michel A, et al
    Serum biomarkers of polyomavirus infection and risk of lung cancer in never smokers.
    Br J Cancer. 2016 Sep 15. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  51. KOTSAKIS A, Matikas A, Koinis F, Kentepozidis N, et al
    A multicentre phase II trial of cabazitaxel in patients with advanced non-small-cell lung cancer progressing after docetaxel-based chemotherapy.
    Br J Cancer. 2016 Sep 8. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    August 2016
  52. EVISON M, Crosbie P, Navani N, Callister M, et al
    How should performance in EBUS mediastinal staging in lung cancer be measured?
    Br J Cancer. 2016 Aug 23. doi: 10.1038/bjc.2016.
    PubMed     Text format    


    July 2016
  53. BROUTIN S, Stewart A, Thavasu P, Paci A, et al
    Insights into significance of combined inhibition of MEK and m-TOR signalling output in KRAS mutant non-small-cell lung cancer.
    Br J Cancer. 2016 Jul 21. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  54. ROBINSON LA, Jaing CJ, Campbell CP, Magliocco A, et al
    Molecular evidence of viral DNA in non-small cell lung cancer and non-neoplastic lung.
    Br J Cancer. 2016 Jul 14. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  55. KARAGOUNIS IV, Kalamida D, Mitrakas A, Pouliliou S, et al
    Repression of the autophagic response sensitises lung cancer cells to radiation and chemotherapy.
    Br J Cancer. 2016 Jul 5. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    June 2016
  56. ZHANG H, Shao H, Golubovskaya VM, Chen H, et al
    Efficacy of focal adhesion kinase inhibition in non-small cell lung cancer with oncogenically activated MAPK pathways.
    Br J Cancer. 2016 Jun 23. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  57. TANG R, Lei Y, Hu B, Yang J, et al
    WW domain binding protein 5 induces multidrug resistance of small cell lung cancer under the regulation of miR-335 through the Hippo pathway.
    Br J Cancer. 2016 Jun 23. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  58. RENAUD S, Seitlinger J, Falcoz PE, Schaeffer M, et al
    Specific KRAS amino acid substitutions and EGFR mutations predict site-specific recurrence and metastasis following non-small-cell lung cancer surgery.
    Br J Cancer. 2016 Jun 23. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  59. BENITEZ-MAJANO S, Fowler H, Maringe C, Di Girolamo C, et al
    Deriving stage at diagnosis from multiple population-based sources: colorectal and lung cancer in England.
    Br J Cancer. 2016 Jun 21. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  60. WALKER AJ, Baldwin DR, Card TR, Powell HA, et al
    Risk of venous thromboembolism in people with lung cancer: a cohort study using linked UK healthcare data.
    Br J Cancer. 2016 Jun 2. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    May 2016
  61. LUO J, Hendryx M, Qi L, Ho GY, et al
    Pre-existing diabetes and lung cancer prognosis.
    Br J Cancer. 2016 May 19. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    March 2016
  62. STEIN SM, James ES, Deng Y, Cong X, et al
    Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer.
    Br J Cancer. 2016;114:737-43.
    PubMed     Text format     Abstract available


  63. BOTZER LE, Maman S, Sagi-Assif O, Meshel T, et al
    Hexokinase 2 is a determinant of neuroblastoma metastasis.
    Br J Cancer. 2016;114:759-66.
    PubMed     Text format     Abstract available


  64. BYRNE NM, Nesbitt H, Ming L, McKeown SR, et al
    Androgen deprivation in LNCaP prostate tumour xenografts induces vascular changes and hypoxic stress, resulting in promotion of epithelial-to-mesenchymal transition.
    Br J Cancer. 2016;114:659-68.
    PubMed     Text format     Abstract available


  65. MARTIN P, Shiau CJ, Pasic M, Tsao M, et al
    Clinical impact of mutation fraction in epidermal growth factor receptor mutation positive NSCLC patients.
    Br J Cancer. 2016;114:616-22.
    PubMed     Text format     Abstract available


  66. JIN Y, Wang J, Ye X, Su Y, et al
    Identification of GlcNAcylated alpha-1-antichymotrypsin as an early biomarker in human non-small-cell lung cancer by quantitative proteomic analysis with two lectins.
    Br J Cancer. 2016;114:532-44.
    PubMed     Text format     Abstract available


  67. KAO SC, Kirschner MB, Cooper WA, Tran T, et al
    A proteomics-based approach identifies secreted protein acidic and rich in cysteine as a prognostic biomarker in malignant pleural mesothelioma.
    Br J Cancer. 2016;114:524-31.
    PubMed     Text format     Abstract available


  68. TEBBUTT NC, Price TJ, Ferraro DA, Wong N, et al
    Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial.
    Br J Cancer. 2016;114:505-9.
    PubMed     Text format     Abstract available


    February 2016
  69. MARSHALL DC, Webb TE, Hall RA, Salciccioli JD, et al
    Trends in UK regional cancer mortality 1991-2007.
    Br J Cancer. 2016;114:340-7.
    PubMed     Text format     Abstract available


    January 2016
  70. NISMAN B, Nechushtan H, Biran H, Peled N, et al
    New ARCHITECT plasma pro-gastrin-releasing peptide assay for diagnosing and monitoring small-cell lung cancer.
    Br J Cancer. 2016 Jan 26. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    December 2015
  71. ZIELINSKI C, Lang I, Beslija S, Kahan Z, et al
    Predictive role of hand-foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer.
    Br J Cancer. 2015 Dec 10. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


  72. RENAUD S, Falcoz PE, Romain B, Olland A, et al
    Reply: Comment on 'KRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colo-rectal cancer'.
    Br J Cancer. 2015;113:1637-8.
    PubMed     Text format    


    November 2015
  73. BAHLEDA R, Hollebecque A, Varga A, Gazzah A, et al
    Phase I study of afatinib combined with nintedanib in patients with advanced solid tumours.
    Br J Cancer. 2015;113:1413-20.
    PubMed     Text format     Abstract available


  74. KUAN FC, Kuo LT, Chen MC, Yang CT, et al
    Overall survival benefits of first-line EGFR tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung cancers: a systematic review and meta-analysis.
    Br J Cancer. 2015;113:1519-28.
    PubMed     Text format     Abstract available


    October 2015
  75. RENAUD S, Falcoz PE, Schaeffer M, Guenot D, et al
    Prognostic value of the KRAS G12V mutation in 841 surgically resected Caucasian lung adenocarcinoma cases.
    Br J Cancer. 2015;113:1206-15.
    PubMed     Text format     Abstract available


    September 2015
  76. ANDREEV K, Trufa ID, Siegemund R, Rieker R, et al
    Impaired T-bet-pSTAT1alpha and perforin-mediated immune responses in the tumoral region of lung adenocarcinoma.
    Br J Cancer. 2015;113:902-13.
    PubMed     Text format     Abstract available


  77. CARDILLO G, Mokhles S, Williams N, Macbeth F, et al
    Comment on: 'KRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colorectal cancer.' Variation in survival associated with proto-oncongenes is not evidence for effectiveness of lung metastasectomy.
    Br J Cancer. 2015 Sep 15. doi: 10.1038/bjc.2015.
    PubMed     Text format    


  78. HASHIBE M, Galeone C, Buys SS, Gren L, et al
    Coffee, tea, caffeine intake, and the risk of cancer in the PLCO cohort.
    Br J Cancer. 2015;113:809-16.
    PubMed     Text format     Abstract available


    July 2015
  79. DI BENEDETTO M, Toullec A, Buteau-Lozano H, Abdelkarim M, et al
    MDA-MB-231 breast cancer cells overexpressing single VEGF isoforms display distinct colonisation characteristics.
    Br J Cancer. 2015 Jul 21. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: